Semaglutide, tirzepatide, retatrutide and what the data really shows.
The headline on every GLP-1 article is weight loss. That undersells what’s happening. The cardiovascular, kidney, and emerging cognitive data on this drug class is, in our view, the most important development in metabolic medicine in a generation. Weight loss is one outcome of a much larger story.
This article is general education and explains mechanism and class-level data — not how we dose individual patients.
When you eat, your gut releases two short-acting peptide hormones called incretins: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). They tell the pancreas to release insulin in proportion to the meal, slow gastric emptying, suppress glucagon, and signal the brain that you’re full. They also have direct effects on cardiovascular tissue, kidney function, and inflammation.
In type 2 diabetes and obesity, the incretin signal is blunted. The drugs in this class — semaglutide, liraglutide, dulaglutide, tirzepatide, retatrutide — are stable, long-acting analogs of these hormones. They restore and amplify the signal.
A pure GLP-1 receptor agonist. The most studied of the family. The SELECT trial (over 17,000 patients with cardiovascular disease and obesity, no diabetes) showed a 20% reduction in major adverse cardiovascular events over a median 40 months. Kidney outcomes (FLOW), heart failure with preserved ejection fraction (STEP-HFpEF), and addiction signals are all positive.
A dual GLP-1 / GIP agonist. Weight-loss efficacy is roughly 50% higher than semaglutide in head-to-head data (SURMOUNT trials). Cardiovascular outcomes data is maturing but trending favorable. Sleep apnea improvement was substantial enough to gain a separate FDA indication.
A triple agonist — GLP-1, GIP, and glucagon receptor — still in late-phase trials. Phase 2 data showed mean weight loss exceeding 24% at 48 weeks, the highest reported for any incretin to date. The glucagon arm adds direct metabolic effects beyond appetite. Not yet FDA-approved; some 503A compounding pharmacies prepare research-grade material under physician oversight.
These drugs restore and amplify the gut-to-brain-to-pancreas signal that tells your body it’s well-fed — with downstream benefits on heart, kidney, and brain that go far beyond appetite.
Three signals matter most for longevity-minded patients:
None of this means GLP medicines are without trade-offs. Lean mass loss, GI side effects, gallbladder disease, and a small pancreatitis signal are all real. The art of the practice is dosing slowly, training hard to preserve muscle, eating enough protein, and stopping or de-escalating when goals are met.
Brand-name GLP-1s (Wegovy, Zepbound) are excellent — when you can get them, and when you can afford them. Supply has been spotty since 2022, and many patients pay $800–$1,300 a month out of pocket. 503A state-licensed compounding pharmacies can prepare semaglutide and tirzepatide for individual patients under a valid physician prescription, typically at a fraction of the cost. We use this pathway for patients who can’t access brand product or for whom dose flexibility matters.
Compounded does not mean inferior. It does mean the practice prescribing it is responsible for clinical evaluation, dose titration, side-effect monitoring, and lab follow-up. That’s the part that’s missing from most “online GLP” services.
Our members get the dose-titration ladders, side-effect rescue plans, lean-mass preservation programming, exit and maintenance strategies, and the lab cadence we actually run.